NASDAQ · Biotechnology
AGEN (AGEN) Stock
$7.99
+4.99%
NASDAQ: AGEN
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
Zacks · Jul 14, 2026
Agenus stock doubles as biotech narrows Phase 3 bet
TheStreet · Jul 14, 2026
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
Zacks · Jul 14, 2026
Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?
Simply Wall St. · Jul 14, 2026
AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment
Stocktwits · Jul 13, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held6.72%
Institutions Held23.70%
Institutions Float Held25.41%
Peer Comparison
About AGEN
AGEN is led by CEO Garo H. Armen, employs 316 people, headquartered in US, publicly traded since 2000.
AGEN stock trades at $7.99 with a market capitalization of $332.72M. The stock is valued at a price-to-earnings (P/E) ratio of 3.04, price-to-book of -1.71, price-to-sales of 2.59. Over the past 52 weeks the stock has ranged between $2.71 and $8.85, and currently trades 9.7% below its 52-week high.
On profitability, AGEN generates a return on equity (ROE) of -38.12%, return on capital employed of -61.22%, an operating margin of -18.42%, a net profit margin of 69.34%.